MFA
NKTR icon

McClarren Financial Advisors’s Nektar Therapeutics NKTR Stock Holding History

McClarren Financial Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10
Closed – – 402
2023
Q4 		$0 Hold
10
– – ﹤0.01% 405
2023
Q3 		$0 Hold
10
– – ﹤0.01% 379
2023
Q2 		$0 Hold
10
– – ﹤0.01% 423
2023
Q1 		$0 Hold
10
– – ﹤0.01% 421
2022
Q4 		$0 Hold
10
– – ﹤0.01% 427
2022
Q3 		$0 Buy
+10
New +$595 ﹤0.01% 323
2022
Q2 		– Sell
-10
Closed – – 179
2022
Q1 		$0 Hold
10
– – ﹤0.01% 297
2021
Q4 		$3K Hold
10
– – ﹤0.01% 282
2021
Q3 		$2K Sell
10
-22
-69% -$5.29K ﹤0.01% 260
2021
Q2 		$8K Buy
32
+22
+220% +$6.09K 0.01% 233
2021
Q1 		$3K Hold
10
– – ﹤0.01% 233
2020
Q4 		$2K Buy
+10
New +$2.58K ﹤0.01% 204

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

McClarren Financial Advisors's NKTR Position: Q1 2024 in Review

McClarren Financial Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 10 shares.

McClarren Financial Advisors first reported a position in NKTR in Q4 2020 and held it in 12 quarters. The position peaked at $8K in Q2 2021. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • McClarren Financial Advisors reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • McClarren Financial Advisors sold 10 Nektar Therapeutics shares in Q1 2024.
  • McClarren Financial Advisors first reported a position in Nektar Therapeutics in Q4 2020 and held it in 12 quarters.
  • McClarren Financial Advisors's Nektar Therapeutics position peaked at $8K in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on McClarren Financial Advisors's 13F filing for Q1 2024, filed 3 May 2024.